[1] |
Das S, Marsden PA. Angiogenesis in glioblastoma[J]. N Engl J Med, 2013, 369(16): 1561-3
|
[2] |
Alexander BM, Cloughesy TF. Adult glioblastoma[J]. J Clin Oncol, 2017, 35(21): 2402-9
|
[3] |
Sampetrean O, Saya H. Modeling phenotypes of malignant gliomas[J]. Cancer Sci, 2017, 32(10): 1111-7
|
[4] |
Taal W, Bromberg JE. chemotherapy in glioma[J]. CNS Oncol, 2015, 4(3): 179-92
|
[5] |
Stavrovskaya AA, Shushanov SS, Rybalkina EY. Problems of glioblastoma multiforme drug resistance[J]. Biochemistry, 2016, 81(2): 91-100
|
[6] |
Fan CH, Liu WL, Cao H, et al. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas[J]. Cell Death Dis, 2013, 4(10): e876-81
|
[7] |
Yi GZ, Liu YW, Xiang W, et al. Akt and beta-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line[J]. J Neurol Sci, 2016, 367(12): 101-6
|
[8] |
West CM, Price P. Combretastatin a4 phosphate[J]. Anticancer Drugs, 2004, 15(3): 179-87
|
[9] |
Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer[J]. Gynecol Oncol, 2017, 145(2): 393-406
|
[10] |
Garon EB, Neidhart JD, Gabrail NY, et al. A randomized Phase II trial of the tumor vascular disrupting agent CACA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer[J]. Onco Targets Ther, 2016, 9(10): 7275-83
|
[11] |
Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer[J]. Clin Cancer Res, 2012, 18(12): 3428-39
|
[12] |
Liu L, Mason RP, Gimi B. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts[J]. Cancer Lett, 2015, 356(2B): 462-9
|
[13] |
Vincent L. Combretastatin a4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling[J]. J Clin Investig, 2005, 115(11): 2992-3006
|
[14] |
陈 灿, 牛 犇, 包 旭, 等. CA4P抗肿瘤作用的实验研究[J]. 华西药学杂志, 2009, 24(6): 609-11
|
[15] |
王 艳, 朱丽媛, 刘 畅, 等. Combretastatin A4 Phosphate对人晶状体上皮细胞增殖及迁移的影响[J]. 中山大学学报: 医学科学版, 2012, 33(1): 8-15
|
[16] |
牛 犇, 方素华, 包 旭, 等. 康普瑞丁磷酸二钠在体内外的抗肿瘤作用[J]. 华西药学杂志, 2007, 22(6): 632-5
|
[17] |
Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets[J]. Semin Cancer Biol, 2015, 35(S): S25-54
|
[18] |
Harris AL. Hypoxia-A key regulatory factor in tumour growth[J]. Nat Rev Cancer, 2002, 2(1): 38-47
|
[19] |
Chen HF, Ma RR, He JY, et al. Protocadherin 7 inhibits cell migration and invasion through E-cadherin in gastric cancer[J]. Tumor Biol, 2017, 39(4): 568835941-9
|
[20] |
Zhang L, Wang GY, Wang L, et al. Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression[J]. Pharmazie, 2011, 66(8): 614-8
|
[21] |
Petit I, Karajannis MA, Vincent L, et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death[J]. Blood, 2008, 111(4): 1951-61
|
[22] |
Izumi Y, Aoshima K, Hoshino Y, et al. Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells[J]. Res Vet Sci, 2017, 112(6): 222-8
|
[23] |
Chen BJ, Zhang W, Gao J, et al. Downregulation of ribosomal protein S6 inhibits the growth of non-small cell lung cancer by inducing cell cycle arrest, rather than apoptosis[J]. Cancer Lett, 2014, 354(2): 378-89
|
[24] |
Lin A, Piao HL, Zhuang L, et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway[J]. Cancer Res, 2014, 74(6): 1682-93
|
[25] |
Xie Q, Sun Z, Chen M, et al. IL-8 up-regulates proliferative angiogenesis in ischemic myocardium in rabbits through phosphorylation of Akt/GSK-3β(ser9)dependent pathways[J]. Int J Clin Exp Med, 2015, 8(8): 12498-507
|
[26] |
Zhang ZW, Zhang HQ, Chen SY, et al. Dihydromyricetin induces mitochondria-mediated apoptosis in HepG2 cells through down-regulation of the Akt/Bad pathway[J]. Nutr Res, 2017, 38(5): 27-33
|
[27] |
Zheng GY, Chen XC, Du J. Inhibitory action of propyl gallate on the activation of SAPK/JNK and p38MAPK induced by cerebral ischem ia-reperfusion in rats[J]. Acta Pharm Sin, 2006, 41(6): 548-54
|
[28] |
Cicenas J. The potential role of Akt phosphorylation in human cancers[J]. Int J Biol Markers, 2008, 23(1): 1-9
|